Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production

Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production

Abatacept may exert its clinical effect on rheumatoid arthritis (RA) by suppressing anti-cyclic citrullinated peptide (CCP) antibody production. This study was undertaken to test this hypothesis by examining the changes of disease activity of RA and anti-CCP antibody levels over time after starting...

Full description

Bibliographic Details
Main Authors: Hisakata Yamada, Tomomi Tsuru, Takeshi Otsuka, Masayuki Maekawa, Hiroshi Harada, Takaaki Fukuda, Hiroshi Tsukamoto, Akira Maeyama, Shigeru Yoshizawa, Ken Wada, Yasuharu Nakashima, Eisuke Shono, Seiji Yoshizawa, Hiroshi Jojima, Masakazu Kondo
Format: Article
Language:English
Published: Taylor & Francis Group 2020-04-01
Series:Immunological Medicine
Subjects:
rheumatoid arthritis
anti-citrullinated protein antibodies
cyclic citrullinated peptide
abatacept
Online Access:http://dx.doi.org/10.1080/25785826.2020.1718833

Internet

http://dx.doi.org/10.1080/25785826.2020.1718833

Similar Items